A Dual‐Acceptor Engineered Second Near‐Infrared Ionic Aggregation‐Induced Emission Luminogen for Mitochondria‐Disrupted Cancer Phototheranostics
Aggregate · 2026-02 · 7 (2)
DOI: 10.1002/agt2.70281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aggregate, online erschienen am 29.01.2026. Verfasst von Yuanyuan You und 11 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Ionic phototheranostic agents have found extensive application in preclinical and clinical practice owing to their excellent biocompatibility and synergistic diagnostic–therapeutic integration. However, they still suffer from certain limitations, such as short absorption/emission wavelengths, poor photostability, aggregation‐caused fluorescence self‐quenching, and diminished phototherapeutic efficacy upon aggregation, which collectively hinder their efficacy in complex clinical scenarios. To address these challenges, a second near‐infrared (NIR‐II) ionic phototheranostic agent, namely DT‐BT‐BIn, is rationally designed and synthesized via an innovative dual‐acceptor engineering strategy. DT‐BT‐BIn ingeniously integrates benzothiadiazole and benzo[ c,d ]indolium as dual‐acceptor units, which successfully achieves superior aggregation‐induced NIR‐II emission characteristics, highly efficient Type I/II photodynamic activity coupled with photothermal effect, and excellent photostability. Moreover, the self‐assembled DT‐BT‐BIn nanoprobes (NPs) can be effectively internalized by cancer cells in vitro. Under irradiation, DT‐BT‐BIn NPs are capable of disrupting mitochondrial membrane potential, thereby inducing apoptotic cell death. Furthermore, in vivo investigations demonstrate DT‐BT‐BIn NPs can effectively accumulate at tumor location, enabling NIR‐II fluorescence/photothermal imaging‐guided precise tumor ablation, while simultaneously maintaining favorable biosafety toward normal tissues. Collectively, this study underscores the considerable promise of the dual‐acceptor strategy in constructing high‐performance NIR‐II ionic phototheranostic agents and provides a new avenue for clinical precision cancer phototherapy.
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
You, Y., Lin, S., Tang, C., Liang, Q., Deng, H., Li, L., Ding, Y., Chen, J., Chen, J., Yan, D., Wang, D., & Chen, X. (2026). A Dual‐Acceptor Engineered Second Near‐Infrared Ionic Aggregation‐Induced Emission Luminogen for Mitochondria‐Disrupted Cancer Phototheranostics. Aggregate, 7(2). https://doi.org/10.1002/agt2.70281
Vancouver
You Y, Lin S, Tang C, Liang Q, Deng H, Li L, et al. A Dual‐Acceptor Engineered Second Near‐Infrared Ionic Aggregation‐Induced Emission Luminogen for Mitochondria‐Disrupted Cancer Phototheranostics. Aggregate. 2026;7(2). doi:10.1002/agt2.70281
BibTeX
@article{You2026,
author = {You, Yuanyuan and Lin, Songling and Tang, Chengwei and Liang, Qiongwen and Deng, Huachan and Li, Lu and Ding, Yuxun and Chen, Jiayi and Chen, Jiachun and Yan, Dingyuan and Wang, Dong and Chen, Xiaohui},
title = {A Dual‐Acceptor Engineered Second Near‐Infrared Ionic Aggregation‐Induced Emission Luminogen for Mitochondria‐Disrupted Cancer Phototheranostics},
journal = {Aggregate},
year = {2026},
volume = {7},
number = {2},
doi = {10.1002/agt2.70281}
}
EUVIMED